USD 5.58
(-2.26%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 49.94 Million USD | -52.7% |
2022 | 105.59 Million USD | 28.79% |
2021 | 81.99 Million USD | 59.07% |
2020 | 51.54 Million USD | 18.34% |
2019 | 43.55 Million USD | 98.19% |
2018 | 21.97 Million USD | -24.42% |
2017 | 29.07 Million USD | 75.71% |
2016 | 16.54 Million USD | -23.98% |
2015 | 21.76 Million USD | -0.2% |
2014 | 21.81 Million USD | 25.66% |
2013 | 17.35 Million USD | -19.36% |
2012 | 21.52 Million USD | -35.23% |
2011 | 33.23 Million USD | -2.08% |
2010 | 33.93 Million USD | -45.44% |
2009 | 62.2 Million USD | -68.9% |
2008 | 200 Million USD | -0.5% |
2007 | 201 Million USD | 102.17% |
2006 | 99.42 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q3 | 74.78 Million USD | 5.99% |
2024 Q1 | 70.29 Million USD | 40.74% |
2024 Q2 | 70.55 Million USD | 0.38% |
2023 FY | 49.94 Million USD | -52.7% |
2023 Q1 | 92.05 Million USD | -12.83% |
2023 Q4 | 49.94 Million USD | -20.66% |
2023 Q3 | 62.94 Million USD | -23.82% |
2023 Q2 | 82.63 Million USD | -10.24% |
2022 Q2 | 75.51 Million USD | -1.47% |
2022 Q1 | 76.63 Million USD | -6.53% |
2022 Q4 | 105.59 Million USD | 30.11% |
2022 Q3 | 81.15 Million USD | 7.48% |
2022 FY | 105.59 Million USD | 28.79% |
2021 Q4 | 81.99 Million USD | 40.17% |
2021 FY | 81.99 Million USD | 59.07% |
2021 Q3 | 58.49 Million USD | 18.09% |
2021 Q2 | 49.53 Million USD | 2.28% |
2021 Q1 | 48.43 Million USD | -6.04% |
2020 Q4 | 51.54 Million USD | 9.16% |
2020 FY | 51.54 Million USD | 18.34% |
2020 Q1 | 50.4 Million USD | 15.73% |
2020 Q2 | 46.99 Million USD | -6.76% |
2020 Q3 | 47.21 Million USD | 0.47% |
2019 Q2 | 48.1 Million USD | -3.61% |
2019 FY | 43.55 Million USD | 98.19% |
2019 Q4 | 43.55 Million USD | -0.3% |
2019 Q3 | 43.68 Million USD | -9.19% |
2019 Q1 | 49.91 Million USD | 127.11% |
2018 Q2 | 23.42 Million USD | -20.42% |
2018 FY | 21.97 Million USD | -24.42% |
2018 Q3 | 23.82 Million USD | 1.71% |
2018 Q4 | 21.97 Million USD | -7.76% |
2018 Q1 | 29.43 Million USD | 1.24% |
2017 Q2 | 19.14 Million USD | 1.03% |
2017 Q3 | 22 Million USD | 14.95% |
2017 Q1 | 18.95 Million USD | 14.51% |
2017 Q4 | 29.07 Million USD | 32.12% |
2017 FY | 29.07 Million USD | 75.71% |
2016 Q2 | 17.17 Million USD | -25.56% |
2016 FY | 16.54 Million USD | -23.98% |
2016 Q1 | 23.07 Million USD | 6.0% |
2016 Q4 | 16.54 Million USD | 5.58% |
2016 Q3 | 15.67 Million USD | -8.74% |
2015 Q3 | 21.03 Million USD | 15.62% |
2015 Q4 | 21.76 Million USD | 3.5% |
2015 Q2 | 18.19 Million USD | -8.14% |
2015 FY | 21.76 Million USD | -0.2% |
2015 Q1 | 19.8 Million USD | -9.2% |
2014 FY | 21.81 Million USD | 25.66% |
2014 Q4 | 21.81 Million USD | 11.37% |
2014 Q1 | 19.38 Million USD | 11.7% |
2014 Q2 | 15.91 Million USD | -17.91% |
2014 Q3 | 19.58 Million USD | 23.06% |
2013 Q2 | 16.13 Million USD | -29.53% |
2013 Q4 | 17.35 Million USD | 11.53% |
2013 FY | 17.35 Million USD | -19.36% |
2013 Q1 | 22.89 Million USD | 6.37% |
2013 Q3 | 15.56 Million USD | -3.55% |
2012 Q3 | 26.04 Million USD | 3.48% |
2012 Q2 | 25.16 Million USD | -34.36% |
2012 Q1 | 38.33 Million USD | 15.36% |
2012 FY | 21.52 Million USD | -35.23% |
2012 Q4 | 21.52 Million USD | -17.34% |
2011 Q1 | 36.54 Million USD | 7.67% |
2011 Q4 | 33.23 Million USD | -12.88% |
2011 Q3 | 38.14 Million USD | 29.98% |
2011 Q2 | 29.34 Million USD | -19.68% |
2011 FY | 33.23 Million USD | -2.08% |
2010 Q1 | 227.99 Million USD | 266.55% |
2010 Q3 | 43.94 Million USD | 11.59% |
2010 Q4 | 33.93 Million USD | -22.77% |
2010 FY | 33.93 Million USD | -45.44% |
2010 Q2 | 39.38 Million USD | -82.73% |
2009 FY | 62.2 Million USD | -68.9% |
2009 Q4 | 62.2 Million USD | -73.43% |
2009 Q3 | 234.1 Million USD | 0.0% |
2008 FY | 200 Million USD | -0.5% |
2008 Q4 | 200 Million USD | 0.0% |
2008 Q1 | 195.33 Million USD | 0.0% |
2007 FY | 201 Million USD | 102.17% |
2006 FY | 99.42 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 85.63% |
Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 89.56% |
Viridian Therapeutics, Inc. | 48.4 Million USD | -3.19% |
Organovo Holdings, Inc. | 2.74 Million USD | -1717.54% |